Annual report
2934.TEDINET S100SX2D
Period2022-06-01 → 2023-05-31
Filed2024-02-21
StandardJapan GAAP
ConsolidatedYes
Data checks23 of 23 passed
Amends S100RRVE. Amended by S100SXUN (2024-02-21).
Key figures · 116
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥16.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales |
| Revenue | ¥11.9bn | 2021-06-01 → 2022-05-31 | Cons. | Net sales |
| Operating income | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Operating income |
| Operating income | ¥731m | 2021-06-01 → 2022-05-31 | Cons. | Operating income |
| Ordinary income | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥712m | 2021-06-01 → 2022-05-31 | Cons. | Ordinary income |
| Profit before tax | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥700m | 2021-06-01 → 2022-05-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.9bn | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥401m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.9bn | 2022-06-01 → 2023-05-31 | Cons. | Profit loss |
| Net income | ¥400m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss |
| Total assets | ¥7.2bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥6.1bn | at 2022-05-31 | Cons. | Assets |
| Total liabilities | ¥4.5bn | at 2023-05-31 | Cons. | Liabilities |
| Total liabilities | ¥1.9bn | at 2022-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.7bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-05-31 | Cons. | Net assets |
| Net assets / equity | ¥1.3bn | at 2021-05-31d | Cons. | Net assets |
| Cash and deposits | ¥1.6bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.0bn | at 2022-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.6bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2021-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥367m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥860m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.5bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.6bn | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-410.6 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.64 | 2021-06-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥86.68 | 2021-06-01 → 2022-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥525.78 | at 2023-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥907.43 | at 2022-05-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 34.1% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.8% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.7% | 2021-06-01 → 2022-05-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 255 | at 2023-05-31 | Cons. | Number of employees |
| Employees | 278 | at 2022-05-31 | Cons. | Number of employees |
| Revenue | ¥9.4bn | 2022-06-01 → 2023-05-31 | Standalone | Net sales |
| Revenue | ¥9.3bn | 2021-06-01 → 2022-05-31 | Standalone | Net sales |
| Revenue | ¥8.5bn | 2020-06-01 → 2021-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥7.1bn | 2019-06-01 → 2020-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥6.1bn | 2018-06-01 → 2019-05-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Operating income |
| Operating income | ¥751m | 2021-06-01 → 2022-05-31 | Standalone | Operating income |
| Ordinary income | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥724m | 2021-06-01 → 2022-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥679m | 2020-06-01 → 2021-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥174m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥367m | 2018-06-01 → 2019-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥723m | 2021-06-01 → 2022-05-31 | Standalone | Income before income taxes |
| Net income | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Profit loss |
| Net income | ¥450m | 2021-06-01 → 2022-05-31 | Standalone | Profit loss |
| Net income | ¥425m | 2020-06-01 → 2021-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥96m | 2019-06-01 → 2020-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥6m | 2018-06-01 → 2019-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥5.8bn | at 2023-05-31 | Standalone | Assets |
| Total assets | ¥5.3bn | at 2022-05-31 | Standalone | Assets |
| Total assets | ¥2.6bn | at 2021-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.0bn | at 2020-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.9bn | at 2019-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.1bn | at 2023-05-31 | Standalone | Liabilities |
| Total liabilities | ¥1.1bn | at 2022-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.8bn | at 2023-05-31 | Standalone | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-05-31 | Standalone | Net assets |
| Net assets / equity | ¥1.3bn | at 2021-05-31d | Standalone | Net assets |
| Net assets / equity | ¥843m | at 2020-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥746m | at 2019-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥814m | at 2023-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.4bn | at 2022-05-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.6bn | at 2021-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥902m | at 2020-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥948m | at 2019-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥831m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥218m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥14m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥8m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥165m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥63m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥94m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥99m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥130m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-357.08 | 2022-06-01 → 2023-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.91 | 2021-06-01 → 2022-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥110.75 | 2020-06-01 → 2021-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.12 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.6 | 2018-06-01 → 2019-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥97.45 | 2021-06-01 → 2022-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥589.16 | at 2023-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥918.35 | at 2022-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥329.99 | at 2021-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥219.25 | at 2020-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥194.13 | at 2019-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 47.4% | at 2023-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.0% | at 2022-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.8% | at 2021-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.5% | at 2020-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.0% | at 2019-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -47.5% | 2022-06-01 → 2023-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.5% | 2021-06-01 → 2022-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 40.3% | 2020-06-01 → 2021-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2019-06-01 → 2020-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.8% | 2018-06-01 → 2019-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,892,098 | at 2023-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,757,616 | at 2022-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2021-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2020-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2019-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 49 | at 2023-05-31 | Standalone | Number of employees |
| Employees | 54 | at 2022-05-31 | Standalone | Number of employees |
| Employees | 46 | at 2021-05-31d | Standalone | Number of employees |
| Employees | 47 | at 2020-05-31d | Standalone | Number of employees |
| Employees | 42 | at 2019-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-06-01 → 2023-05-31 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2022-06-01 → 2023-05-31 | ¥765,000 |
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2023-05-31 | −¥186m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2023-05-31 | −¥186m |
| Reconciling Itemsreconciling | segment assets | at 2023-05-31 | ¥1.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2023-05-31 | −¥729m |
| Healthcare Marketing Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥4m |
| Healthcare Marketing Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥5m |
| Healthcare Marketing Businessreportable segment | employees | at 2023-05-31 | 48 pure |
| Healthcare Marketing Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥5.2bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥5.1bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥185m |
| Healthcare Marketing Businessreportable segment | segment assets | at 2023-05-31 | ¥1.1bn |
| Healthcare Marketing Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥39m |
| Healthcare Sales Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥1.1bn |
| Healthcare Sales Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥4m |
| Healthcare Sales Businessreportable segment | employees | at 2023-05-31 | 48 pure |
| Healthcare Sales Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥4.1bn |
| Healthcare Sales Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥4.1bn |
| Healthcare Sales Businessreportable segment | segment assets | at 2023-05-31 | ¥2.4bn |
| Healthcare Sales Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | −¥28m |
| Medical Care Sales Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥288m |
| Medical Care Sales Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥14m |
| Medical Care Sales Businessreportable segment | employees | at 2023-05-31 | 144 pure |
| Medical Care Sales Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥7.7bn |
| Medical Care Sales Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥7.7bn |
| Medical Care Sales Businessreportable segment | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥564,000 |
| Medical Care Sales Businessreportable segment | segment assets | at 2023-05-31 | ¥2.4bn |
| Medical Care Sales Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | −¥1.1bn |
| —segment total | employees | at 2023-05-31 | 255 pure |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-06-01 → 2023-05-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-06-01 → 2023-05-31 | ¥23m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2023-05-31 | ¥17.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2023-05-31 | ¥16.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥186m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-05-31 | ¥5.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2023-05-31 | −¥1.1bn |
| Reconciling Itemsreconciling | capex | 2021-06-01 → 2022-05-31 | ¥5m |
| Reconciling Itemsreconciling | depreciation | 2021-06-01 → 2022-05-31 | ¥5m |
| Reconciling Itemsreconciling | revenue | 2021-06-01 → 2022-05-31 | −¥54m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-06-01 → 2022-05-31 | −¥54m |
| Reconciling Itemsreconciling | segment assets | at 2022-05-31 | ¥2.7bn |
| Reconciling Itemsreconciling | segment profit | 2021-06-01 → 2022-05-31 | −¥425m |
| Healthcare Marketing Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥362m |
| Healthcare Marketing Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥2m |
| Healthcare Marketing Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥3.9bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥3.8bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2021-06-01 → 2022-05-31 | ¥54m |
| Healthcare Marketing Businessreportable segment | segment assets | at 2022-05-31 | ¥1.3bn |
| Healthcare Marketing Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥37m |
| Healthcare Sales Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥703,000 |
| Healthcare Sales Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥3.0bn |
| Healthcare Sales Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥3.0bn |
| Healthcare Sales Businessreportable segment | segment assets | at 2022-05-31 | ¥251m |
| Healthcare Sales Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥779m |
| Medical Care Sales Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥588m |
| Medical Care Sales Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥3m |
| Medical Care Sales Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥5.0bn |
| Medical Care Sales Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥5.0bn |
| Medical Care Sales Businessreportable segment | segment assets | at 2022-05-31 | ¥1.9bn |
| Medical Care Sales Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥339m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-06-01 → 2022-05-31 | ¥950m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-06-01 → 2022-05-31 | ¥5m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-06-01 → 2022-05-31 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-06-01 → 2022-05-31 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-06-01 → 2022-05-31 | ¥54m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-05-31 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-06-01 → 2022-05-31 | ¥1.2bn |
| Healthcare Marketing Businessreportable segment | employees | at 2023-05-31 | 10 pure |
| Healthcare Sales Businessreportable segment | employees | at 2023-05-31 | 19 pure |
| Medical Care Sales Businessreportable segment | employees | at 2023-05-31 | 8 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,468
| Item | Context | Value | Unit |
|---|---|---|---|
| Audit fees total | Prior1YearDuration | 27930000 | JPY |
| Non audit fees total | Prior1YearDuration | 1000000 | JPY |
| Audit fees total | CurrentYearDuration | 42220000 | JPY |
| Non audit fees total | CurrentYearDuration | 7240000 | JPY |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 81762000 | JPY |
| Fixed remuneration remuneration by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 81762000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | － | JPY |
| Retirement benefits remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | － | JPY |
| Non monetary remuneration remuneration by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 4 | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 2700000 | JPY |
| Fixed remuneration remuneration by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 2700000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | － | JPY |
| Retirement benefits remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | － | JPY |
| Non monetary remuneration remuneration by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_CorporateAuditorsExcludingOutsideCorporateAuditorsMember | 1 | |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | 13800000 | JPY |
| Fixed remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | 13800000 | JPY |
| Performance based remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | － | JPY |
| Retirement benefits remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | － | JPY |
| Non monetary remuneration remuneration by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | － | JPY |
| Number of directors and other officers remuneration etc by category of directors and other officers | CurrentYearDuration_OutsideDirectorsAndOtherOfficersMember | 5 | |
| Number of issues shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | 1 | |
| Carrying amount shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | 40002000 | JPY |
| Number of issues shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | － | |
| Carrying amount shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | － | JPY |
| Number of issues shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | 1 | |
| Total acquisition cost for increased shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | 40002000 | JPY |
| Number of issues shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearInstant | － | |
| Total acquisition cost for increased shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | JPY |
| Cash and deposits | Prior1YearInstant | 2956408000 | JPY |
| Cash and deposits | CurrentYearInstant | 1648360000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 1334228000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 1688506000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 407803000 | JPY |
| Merchandise and finished goods | CurrentYearInstant | 792674000 | JPY |
| Work in process | Prior1YearInstant | 21104000 | JPY |
| Work in process | CurrentYearInstant | 20558000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 39218000 | JPY |
| Raw materials and supplies | CurrentYearInstant | 51725000 | JPY |
| Prepaid expenses | Prior1YearInstant | 126832000 | JPY |
| Prepaid expenses | CurrentYearInstant | 148301000 | JPY |
| Short term loans receivable | Prior1YearInstant | － | JPY |
| Short term loans receivable | CurrentYearInstant | 30000000 | JPY |
| Other ca | Prior1YearInstant | 39587000 | JPY |
| Other ca | CurrentYearInstant | 301421000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -3788000 | JPY |
| Allowance for doubtful accounts ca | CurrentYearInstant | -9386000 | JPY |
| Current assets | Prior1YearInstant | 4921394000 | JPY |
| Current assets | CurrentYearInstant | 4672161000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 23 of 23 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |